 | | Vol. 12.36 – 24 September, 2021 |
| |
|
|
| Scientists developed a fluorescent molecular rotor that specifically targets the prostate-specific membrane antigen, an established marker for prostate cancer.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors identified the novel transcriptional factor ZNF507 as a key mediator in the progression of prostate cancer to an aggressive state.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Scientists showed that nobiletin, a polymethoxylated flavonoid derived from the peel of citrus fruits, exerted a potent anticancer activity via inducing G0/G1 phase arrest and enhancing the sensitivity of cells to enzalutamide in androgen receptor splice variant 7 (AR-V7) positive prostate cancer cells.
[Cell Death & Disease] |
|
|
|
| Researchers found lnc-OPHN1-5, which lies close to the androgen receptor (AR) gene on chromosome X, increased prostate cancer Enzalutamide sensitivity via decreasing AR protein expression and associated activity.
[Cell Death & Disease] |
|
|
|
| The authors reported that MCOLN2 expression was significantly elevated in prostate cancer tissues, and associated with poor prognosis. Overexpression of MCOLN2 promoted prostate cancer cells proliferation, migration and invasion.
[British Journal of Cancer] |
|
|
|
| Scientists showed that prostate cancer cells grown in either charcoal-stripped serum or exposed to the antiandrogen, bicalutamide, underwent a senescent growth arrest marked by morphological changes, upregulated senescence-associated-β-galactosidase, cathepsin D accumulation, and expression of the senescence-associated secretory phenotype.
[Biochemical Pharmacology] |
|
|
|
| Investigators confirmed that KIF3C was highly expressed in prostate cancer tissues and cell lines. Further, functional tests have proven that KIF3C could promote the growth migration and invasion of prostate cancer.
[Aging] |
|
|
|
| Researchers examined the expression of DDR1 in prostate cancer, and assessed its potential value as a prognostic marker, as a function of grade, stage and other clinicopathologic parameters.
[Cancer Cell International] |
|
|
|
|
| After generally reviewing and comparing the inflammatory responses in autoimmune diseases and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), the authors presume that CP/CPPS is more likely to be defined as an autoimmune disease.
[Archivum Immunologiae et Therapiae Experimentalis] |
|
|
|
|
| Cyclica and IMPACT Therapeutics announced that they have entered to a collaboration agreement on IMPACT Therapeutics’ differentiated targeted anti-cancer drug development.
[Cyclica] |
|
|
|
| Paige announced that the FDA has granted de novo marketing authorization for Paige Prostate, a clinical-grade AI solution for prostate cancer detection.
[Paige] |
|
|
|
|
| October 4 – 6, 2021
Virtual |
|
|
|
|
|
| | The University of New Mexico – Albuquerque, New Mexico, United States |
|
|
|
| | Houston Methodist Research Institute – Houston, Texas, United States |
|
|
|
| Zhejiang University School of Medicine – Hangzhou, China |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
